<DOC>
	<DOC>NCT00688012</DOC>
	<brief_summary>A placebo-controlled, double-blind, randomized, single dose, dose escalating trial in healthy men to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPC3649.</brief_summary>
	<brief_title>Safety Study of SPC3649 in Healthy Men</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Healthy Volunteers BMI: 1928 kg/m2 No clinically significant disease/disorder Screening laboratory tests without clinically significant abnormalities, must agree to use condoms during intercourse for one week after study drug infusion Following receipt of verbal and written information about the study, the subject must provide signed informed consent before any study related activity is carried out. Heavy exercise within the past 7 days Alcohol intake&gt; 21 units weekly Regular smoker Received experimental drug within 30 days of study entry Planned participation in any experimental study during the study period HIVAb, HBsAg and/or HCV Ab positive History of specific allergy Current use of any drug or narcotics.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>antisense</keyword>
	<keyword>microRna antagonist</keyword>
	<keyword>anti-miR-122</keyword>
	<keyword>Safety in healthy volunteers</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>